Gator Capital Management LLC Purchases New Shares in Kenvue Inc. $KVUE

Gator Capital Management LLC purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 78,564 shares of the company’s stock, valued at approximately $1,355,000.

A number of other institutional investors have also made changes to their positions in KVUE. Norges Bank bought a new stake in Kenvue during the 4th quarter worth about $756,862,000. Cibc World Markets Corp bought a new stake in Kenvue during the 4th quarter worth about $162,193,000. Van ECK Associates Corp raised its holdings in Kenvue by 101.3% during the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after purchasing an additional 9,240,434 shares during the last quarter. ING Groep NV raised its holdings in Kenvue by 1,311.9% during the 4th quarter. ING Groep NV now owns 9,856,090 shares of the company’s stock worth $170,018,000 after purchasing an additional 9,157,999 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in Kenvue by 603.8% during the 4th quarter. Bank of Montreal Can now owns 9,384,200 shares of the company’s stock worth $161,877,000 after purchasing an additional 8,050,823 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Insider Activity at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.59% of the company’s stock.

Kenvue Price Performance

Shares of KVUE opened at $18.13 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The stock has a 50 day simple moving average of $17.43 and a 200 day simple moving average of $17.53. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87. The firm has a market capitalization of $34.80 billion, a PE ratio of 21.32, a P/E/G ratio of 1.37 and a beta of 0.54.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. During the same period in the previous year, the firm earned $0.24 EPS. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is presently 97.65%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Citigroup dropped their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Canaccord Genuity Group boosted their price objective on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Finally, Weiss Ratings cut Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.